into replication the sentinel SNV (P < 1 × 10 −5 ) from loci that are non-overlapping (r 2 < 0.2) with the GWAS findings. Overall, we take sentinel SNVs from 240 loci into replication: 218 from GWAS and 22 from exome analysis (r 2 < 0.2 and >500 kb from previously reported BP SNVs at the time of analysis and not annotated to previously reported BP-associated genes; Supplementary Table 2) .
The replication resources comprise individuals of European ancestry from a large BP meta-analysis consortium (ICBP cohorts listed in the Supplementary Note) and further cohorts with 1000 Genomes data for GWAS (Supplementary Table 3 ) and two large BP exome consortia. We use P < 5 × 10 −8 to denote genome-wide significance in the combined (discovery and replication) meta-analyses, with P < 0.01 for support in the replication data alone and concordant direction of effect. Additionally, we take forward for replication potential secondary signals at 51 previously reported BP loci at the time of analysis (excluding the human leukocyte antigen (HLA) region).
To better understand the functional consequences of our findings, we carry out a series of in silico investigations and experimental analysis of gene expression in relevant vascular tissue for selected putative functional SNVs (Supplementary Fig. 1 ).
RESULTS

Genetic variants at novel loci at time of analysis
Of the 240 loci taken forward to replication, we validated 107 loci at P < 5 × 10 −8 , of which 102 derived from the GWAS analysis were replicated and subjected to meta-analysis in a total of 330,956 individuals ( Tables 1-3 and Supplementary Figs. 2a-c and 3a) , and a further 5 loci from the exome analysis in a total of 422,604 individuals ( Tables 1-3 , Supplementary Fig. 3b and Supplementary Tables 4-6). Thirty-two of these validated loci are novel findings. Since the time of analysis, the remaining 75 loci have also been reported in another study 15 , although at least 53 of these were previously unvalidated ( Tables 1-3) ; Elevated blood pressure is the leading heritable risk factor for cardiovascular disease worldwide. We report genetic association of blood pressure (systolic, diastolic, pulse pressure) among UK Biobank participants of European ancestry with independent replication in other cohorts, and robust validation of 107 independent loci. We also identify new independent variants at 11 previously reported blood pressure loci. In combination with results from a range of in silico functional analyses and wet bench experiments, our findings highlight new biological pathways for blood pressure regulation enriched for genes expressed in vascular tissues and identify potential therapeutic targets for hypertension. Results from genetic risk score models raise the possibility of a precision medicine approach through early lifestyle intervention to offset the impact of blood pressure-raising genetic variants on future cardiovascular disease risk.
Genome-wide association analysis identifies novel blood pressure loci and offers biological insights into cardiovascular risk A full list of authors and affiliations appears at the end of the paper. Elevated blood pressure (BP) is a strong, heritable [1] [2] [3] [4] and modifiable driver of risk for stroke and coronary artery disease and is a leading cause of global mortality and morbidity 5, 6 . At the time of analysis, genome-wide association study (GWAS) meta-analyses, and analyses of custom or exome content, had identified and replicated genetic variants of mostly modest or weak effect on BP at over 120 loci [7] [8] [9] [10] [11] . Here we report association analyses between BP traits and genetic variants among ~140,000 participants in UK Biobank, a prospective cohort study of 500,000 men and women aged 40-69 years with extensive baseline phenotypic measurements, stored biological samples 12 and follow-up by electronic health record linkage 13 . We undertake independent replication in large international consortia and other cohorts, providing robust validation of our findings and new biological insights into BP regulation.
Our study design is summarized in Figure 1 . Briefly, data are available for 152,249 UK Biobank participants genotyped using a customized array (including GWAS and exome content) and with genome-wide imputation based on 1000 Genomes and UK10K sequencing data 14 . (Further details on the UK Biobank imputation are available at the UK Biobank website.) After quality measures and exclusions (Online Methods), we study 140,886 unrelated individuals of European ancestry with two seated clinic BP measurements using the Omron HEM-7015IT device (Supplementary Table 1 ). We carry out GWAS analyses of systolic (SBP) and diastolic (DBP) blood pressure and of pulse pressure (PP) using single-variant linear regression under an additive model, based on ~9.8 million single-nucleotide variants (SNVs) with minor allele frequency (MAF) ≥1% and imputation quality score (INFO) >0.1. For SNVs with P < 1 × 10 −6 , we take forward for replication the sentinel SNV (that is, the SNV with the lowest P value) at each locus, defined by linkage disequilibrium (LD) r 2 ≥ 0.2, within a 1-Mb interval. We similarly analyze exome content for variants with MAF ≥0.01%, including rare variants, taking 4 0 4 VOLUME 49 | NUMBER 3 | MARCH 2017 Nature GeNetics A r t i c l e s hence, we have now validated these loci for the first time. We therefore present results for all 107 validated loci in our study. Most SNVs also showed association with hypertension in the UK Biobank data: for example, 93 of the 107 validated sentinel SNVs were nominally significant (P < 0.01) (Supplementary Table 7) .
Of the 107 validated loci, 24 were reported for association with SBP as the primary trait (most significant from combined meta-analysis), 41 were reported for DBP and 42 were reported for PP, although many loci were associated with more than one BP trait ( Supplementary Fig. 4 ). For example, in the combined meta-analysis, 24 validated loci were associated with both SBP and DBP, 11 were associated with SBP and PP, 1 was associated with DBP and PP, and 4 loci (NADK-CPSF3L, GTF2B, METTL21A-AC079767.3 and PAX2) were associated with all three traits at genome-wide significance (Fig. 2) .
After conditional analysis on the sentinel SNV at each locus, we identified an independent validated secondary SNV at 5 of the 107 loci (Supplementary Tables 8a and 9 ). In comparison with previously reported SNVs at the time of analysis, the contribution of our validated loci increases the percentage of trait variance explained by ~1%, for example, to 3.56% for SBP.
We report signals at known hypertension drug targets, including the ACE (angiotensin-converting enzyme) locus (rs4308, P = 6.8 × 10 −14 , ACE inhibitors), CACNA2D2 (rs743757, P = 2.4 × 10 −10 , calcium channel blockers), MME (rs143112823 in the RP11-439C8.2 locus, P = 1.4 × 10 −14 , omapatrilat), ADRA2B (rs2579519 in the GPAT2-FAHD2CP locus, P = 4.8 × 10 −12 , beta blockers), SLC14A2 (rs7236548, P = 2.0 × 10 −18 , nifedipine) and PDE5A (phosphodiesterase 5A; rs66887589, P = 3.4 × 10 −15 , sildenafil).
Additionally, we evaluated our validated SNVs, where available, in cohorts of non-European ancestry [9] [10] [11] , while recognizing that these analyses are likely underpowered (Supplementary Table 10 ). We found concordance in direction of effect (P < 0.05) for GWAS SNVs for all three BP traits among individuals of East Asian ancestry and for DBP for individuals of South Asian ancestry, also for exome SNVs among individuals of Hispanic ancestry, pointing to trans-ancestry effects for many of the BP-associated variants.
A PhenoScanner 16 search showed that 27 of our 107 validated sentinel SNVs (or proxies; r 2 ≥ 0.8) exhibited genome-wide significant associations with other traits (Supplementary Fig. 5a) on the causal pathway 17 ), cardiovascular risk factors (for example, lipids, height and body mass index) and non-cardiovascular traits (for example, lung function, cancer and Alzheimer's disease).
Variants at previously reported loci at time of analysis
In conditional analyses, we identified 20 secondary SNVs (15 common, 1 rare and 4 low-frequency variants) that were conditionally independent of the BP-associated SNVs at 16 previously reported loci at the time of analysis (Supplementary Tables 8b, 11 and 12). Nine of these SNVs have been reported since the time of analysis; hence, we identify 14 new secondary SNVs at 11 loci. One rare variant (rs138582164, MAF = 0.1%) in the CDH17 locus predicted to act as an exonic stopgain mutation at the GEM gene was associated with a relatively large effect on PP (3.5 mm Hg per allele copy; Supplementary Table 8b) . At three previously reported loci (EBF1, PDE3A and JAG1), we identified multiple independent secondary SNVs in addition to the previously reported SNVs (Supplementary Table 11 ). The UK Biobank data showed support (P < 0.01) for 119 of 122 previously reported BP loci at the time of analysis (159 of 163 SNVs) for one or more BP traits ( Supplementary Fig. 2a-c and Supplementary  Table 13 ). We did not find support for one SNV (rs11066280, RPL6-ALDH1) identified from a GWAS of East Asian ancestry 18 , which may indicate ancestry-specific effects. We compared the MAF and effect sizes in UK Biobank with published results of previously reported variants at the time of analysis (Supplementary Fig. 6 ), finding consistency of results between the two sources of data.
We also examined findings for low-frequency and rare gene mutations previously reported to be associated with monogenic hypertension disorders 19 and included on the UK Biobank gene array. Despite lack of power overall, the variant with the lowest P value (rs387907156, KLH3, MAF = 0.02%) had a seemingly large effect on BP: 8.2 mm Hg (standard error (s.e.) = 4.1, P = 0.046) per allele for SBP and 5.6 mm Hg (s.e. = 2.6, P = 0.048) for PP (Supplementary Table 14) .
Functional analyses
We annotated the 107 validated loci to 212 genes (on the basis of LD r 2 ≥ 0.8) and sought putative function from in silico analyses and gene expression experiments. Candidate genes with the strongest supporting evidence are indicated in the last column of Supplementary Table 4 with an indication of the supporting data source. All genome-wide significant variants in LD (r 2 > 0.8) with the variants reported here, ranked by supporting evidence, are annotated in Supplementary Table 15 . Of the 107 validated sentinel SNVs, 3 were indels; all other variants were SNPs. We identified nonsynonymous SNVs at 13 of the 107 validated loci (Supplementary Table 16 ), 3 of which were predicted to be damaging (ANNOVAR) in TFAP2D (rs78648104), NOX4 (rs56061986) and CCDC141 (rs17362588; reported to be associated with heart rate 20 ) (Supplementary Fig. 5a ). Beyond the coding regions, we identify 29 SNVs in 3′ UTRs that were predicted to significantly weaken or cause loss of microRNA (miRNA) regulation by altering the recognition motif in 7 genes and to strengthen or create target sites for miRNA binding in 13 genes (based on miRNASNP db; Supplementary Table 16) .
From our expression quantitative trait locus (eQTL) analysis (Genotype-Tissue Expression (GTEx)), 59 of the 107 validated loci contained variants with eQTLs in at least one tissue (Supplementary Table 17 ); arterial tissue had the largest number of loci with eQTLs ( Supplementary Fig. 7) , with targeted in silico analysis showing six loci with eQTLs in arterial tissue (Supplementary Table 16 ). For example, the GTEx tibial artery eQTL in SF3A3 (rs4360494) showed strong in silico supporting evidence, including an arterial 
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DNase I-hypersensitive site within which the major C allele removes a predicted AP-2-binding site (Supplementary Fig. 8 ). Hence, we prioritized this gene for in vitro functional analysis. By considering all loci reported here (our 107 validated loci and previously reported loci at the time of analysis), our DEPICT analysis identified enrichment of expression across 31 tissues and cell types ( Supplementary Fig. 9 and Supplementary Table 18), with the greatest enrichment in arteries (P = 1.9 × 10 −6 , false discovery rate (FDR) < 1%). We used FORGE to investigate and identify significant (FDR, P < 0.05) cell-type-specific enrichment within DNase I-hypersensitive sites in a range of tissues, including dermal and lung microvascular endothelial cell types and cardiac fibroblasts (Supplementary Fig. 10 ).
For a set of curated candidate regulatory SNVs from our 107 validated loci (Supplementary Note), widespread enrichment was found in microvascular endothelium, aortic smooth muscle, aortic fibroblasts, vascular epithelium, heart and skin (Supplementary Fig. 10 ). In addition, we identified significant enrichment of histone marks in a wide range of cell types, including strong enrichment for trimethylation of histone H3 at lysine 4 (H3K4me3; an activating modification found near promoters) in umbilical vein endothelial cells (HUVECs) (Supplementary Fig. 11 ). To explore expression specifically at the level of cardiovascular cell types, we used Fantom5 reference transcript expression data (Online Methods) to cluster the 212 genes annotated to our 107 validated loci according to tissue specificity (Supplementary Table 19 ). In keeping with vascular mediation of genetic influence, we identified diphenyleneiodonium, an inhibitor of flavin-containing oxidases, including NAD(P)H oxidase (NOX), which is reported to reverse endothelial dysfunction (and hypertension) in a rat model 21 .
To identify long-range target genes of noncoding variants, we used chromatin interaction (Hi-C) data from HUVECs, as enhancers and silencers often form chromatin loops with their target promoter. In most loci, the strongest promoter interaction involved a gene in high LD with the SNV, but for 21 loci we found a distal potential target gene (Supplementary Table 16 ). Pathway analysis of the distal genes showed the greatest enrichment in regulators of cardiac hypertrophy.
We evaluated pleiotropy using the Genomic Regions Enrichment of Annotations Tool (GREAT) to study enrichment of mouse phenotype and human disease ontology terms across all loci reported here. These PP, pulse pressure; chr., chromosome; EA, effect allele; EAF, effect allele frequency in UK Biobank; β, effect estimate; s.e., standard error of effect; N, total sample size analyzed.
a Named according to the nearest annotated gene(s). b Given with respect to Build 37. c Loci published since our analysis 15 are indicated for GERA (G), GERA + ICBP (HapMap) (GI) or GERA + ICBP (HapMap) + UKB (GIU) analyses.
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A r t i c l e s highlighted cardiovascular system abnormalities and vascular disease as the most highly enriched terms ( Supplementary Fig. 5b,c) . Collectively, evidence from eQTLs, DEPICT, DNase I-hypersensitive sites, histone marks, Hi-C data and ontological analyses indicates predominant vascular and cardiovascular tissue involvement for genes within the BP-associated loci.
We also looked for association of our validated sentinel SNVs with metabolomic signatures. Three SNVs within the NOX4, KCNH4 and LHFPL2 loci showed significant associations (family-wise error rate < 5%) with lipoprotein subfractions from 1 H nuclear magnetic resonance (NMR) spectroscopy analysis of 2,000 Airwave study samples (Supplementary Tables 20 and 21) . The results for these variants suggest a link between BP regulation and lipid metabolism. Eleven SNVs (including at the LHFPL2 locus) showed association (familywise error rate < 5%) with metabolites in blood or urine from the publicly available Metabolomics GWAS Server resource based on mass spectrometry 22, 23 (Supplementary Table 21) , including sugar acids, sphingolipids, fatty acids, glycerophospholipids, organic acids and benzene derivatives.
Several genes and variants with putative function were highlighted in our in silico analysis as having biological support (for example, eQTLs or nonsynonymous SNVs), and those with novelty and tractability to laboratory investigation (for example, expression in available tissue models) were prioritized. Sentinel variants in three genes that were highly significant in the combined meta-analysis (Tables 2 and 3) were selected for experimental testing and were successfully genotyped, each for at least 100 samples. We selected ADAMTS7 because of strong biological support (for example, the mouse knockout phenotype), SF3A3 because of eQTLs and NOX4 because it contains a rare nonsynonymous SNV (Supplementary Table 9) , in addition to common variant associations. We used qPCR to study the impact of these sentinel variants on gene expression in human VSMCs and endothelial cells (Online Methods). For SF3A3, the major C allele of variant rs4360494 associated with increased PP (0.278 (±0.03 (s.e.)) mm Hg, P = 3.7 × 10 −16 , N = 307,682) was associated with SF3A3 expression in human VSMCs, although not in endothelial cells (Supplementary Fig. 13a) Figure 2 Venn diagram of the 107 validated loci from our study. This diagram shows concordance of significant associations across the three BP phenotypes for the 107 validated sentinel variants (tables 1-3) from both the GWAS and exome analyses, according to genome-wide significance in the combined meta-analysis. The locus names labeled within the Venn diagram correspond to those in tables 1-3 and relate to the nearest annotated gene. The locus names in bold highlight the 32 loci that are reported for the first time in our study. SBP, systolic blood pressure; DBP, diastolic blood pressure; PP, pulse pressure. in ADAMTS7 associated with lower DBP (0.238 (±0.03) mm Hg, P = 5.1 × 10 −12 , N = 244,143) was associated with reduced ADAMTS7 expression in human VSMCs (Supplementary Fig. 13b) , while the minor A allele of SNV rs2289125 at the NOX4 locus associated with lower PP (-0.377 (±0.04) mm Hg, P = 9.1 × 10 −22 , N = 282,851) correlated with increased NOX4 expression in endothelial cells although not VSMCs (Supplementary Fig. 13c ). Our study thus finds evidence for novel cis-eQTLs in ADAMTS7 and NOX4 in addition to validating the previously reported GTEx eQTL in SF3A3, and it supports the vascular expression of these genes.
Genetic risk score analyses
We created an unbiased genetic risk score (GRS) ( Supplementary  Table 22 ) to evaluate, in an independent cohort (Airwave; Online Methods), the impact of the combination of all loci reported here on BP levels and risk of hypertension. When compared with the lowest quintile of the distribution of the GRS, individuals >50 years old in the highest quintile had sex-adjusted mean SBP that was 9.3 mm Hg higher (95% confidence interval (CI) = 6.9 to 11.7 mm Hg, P = 1.0 × 10 −13 ) and an over twofold higher risk of hypertension (odds ratio (OR) = 2.32, 95% CI = 1.76 to 3.06, P = 2.8 × 10 −9 ) as compared with individuals in the lowest quintile ( Fig. 3 and Supplementary Table 23) . Similar results were obtained from GRS associations with BP and hypertension within UK Biobank (Supplementary Table 24 ). In UK Biobank-based on self-reported health data, record linkage to Hospital Episode Statistics and mortality follow-up data (Supplementary Table 25 )-we showed that the GRS was associated with increased risk of stroke, coronary heart disease and all cardiovascular outcomes; comparing the upper and lower quintiles of the GRS distribution, sexadjusted odds ratios were 1.34 (95% CI = 1.20 to 1.49, P = 1. Table 27 ). supplementary table 16 , based on knockout (KO) phenotype and previously reported BP biology or a strong functional rationale: eQTL, nonsynonymous SNV or Hi-C data. Multiple lines of evidence indicate the central importance of the vasculature in BP regulation, and we thus highlight existing drugged (*) and druggable (#) targets among these genes. Illustrations used elements with permission from Servier Medical Art. We note that some druggable genes may carry a safety liability, such as GJA1, which has known association with QT interval 20 .
DISCUSSION
A key attribute of this study is the combination of a large, single discovery sample with standardized BP measurement and dense 1000 Genomes and UK10K imputation, yielding a high-quality data set with ~9.8 million variants 14 , taking advantage of major international consortia for parallel replication of common and low-frequency variants. In total, we include GWAS data from 330,956 individuals and exonic SNVs from a total of 422,604 individuals. This strategy resulted in the identification of 107 robustly validated loci for BP traits, including 32 loci that have not previously been reported, and at least 53 further loci were validated for the first time. Despite its size, our study is still underpowered to find low-frequency variants. Our findings are mostly common variants, with modest effect sizes that are similar to those for variants previously reported at the time of analysis (Supplementary Fig. 14) . The lack of rare variant discovery could also be due to the challenge of detecting rare variants from imputed data. There may be greater potential for identifying rare variants from the future release of genetic data for all 500,000 UK Biobank participants. Our findings point to new biology as well as highlighting gene regions in systems that have previously been implicated in the genetics of BP. Several of our validated loci affect atherosclerosis or vascular remodeling (ADAMTS7, THBS2 and CFDP1) and exhibit locus pleiotropy in previous GWAS for coronary artery disease or carotid intimal media thickness [24] [25] [26] (Fig. 4 and Supplementary Fig. 5a ). In previous work, we have shown that expression of ADAMTS7 is upregulated and increases VSMC migration in response to vascular injury in relation to a distinct coronary artery variant (rs3825807; not in LD with our sentinel SNV, r 2 = 0.17) (ref. 27 ). In endothelial cells, ADAMTS7 encodes a metalloproteinase to cleave thrombospondin-1 encoded by THBS2, and this cleavage leads to reduced endothelial cell migration and has a role in neointimal repair in the vessel wall 27 . Our functional work indicates that the allele associated with lower DBP is also associated with lower ADAMTS7 expression in human VSMCs; this fits with the mouse knockout that exhibits reduced atherosclerosis. SF3A3 encodes a splicing factor with no previous links to BP other than our reported association and eQTL. At the CFDP1 locus, our sentinel SNV is in high LD (r 2 = 0.95) with a variant previously associated with carotid intimal medial thickness. Collectively, our findings highlight a potential common mechanism among these genes in vascular remodeling that has previously been observed in smallresistance arteries in essential hypertension 28 .
NADPH oxidase 4 (NOX4) has an established role in the endothelium, where it enhances vasodilatation and reduces BP in vivo 29 . This oxidase generates reactive oxygen species in the endothelium and may contribute to salt-sensitive hypertension in the kidney and the vasculature [30] [31] [32] . We found that the allele of the common variant at the NOX4 locus correlates with increased tissue-specific NOX4 expression in endothelial cells rather than VSMCs (Supplementary Fig. 13c) . NOX4 mediates endothelial cell apoptosis and facilitates vascular collagen synthesis, contributing to endothelial dysfunction and arterial stiffness, and may explain the association with PP 33, 34 .
We identify several loci containing genes involved in vascular signaling and second messenger systems, such as PDE5A and PDE10A [35] [36] [37] . The phosphodiesterase PDE5A hydrolyzes cyclic GMP and is inhibited by sildenafil, which leads to vasodilatation 38 . This finding fits with our previous discoveries of a role for gene loci encoding elements of the natriuretic peptide-nitric oxide pathway and guanylate cyclase signaling systems in BP regulation 18, 39, 40 . Our findings strengthen the case for evaluating the opportunity to repurpose PDE5A inhibitors for use in hypertension.
The importance of microvascular function is emphasized by the identification of solute carrier transporters such as SLC14A2 encoding a urea transporter, which has previously been linked to autosomal dominant Streeten-type orthostatic hypotensive disorder 41 and BP response to nifedipine, a calcium channel blocker antihypertensive drug 42 . SLC8A1 encodes a sodium-calcium exchanger expressed in cardiomyocytes that alters cardiac contractility and hypertrophy. This shows abnormal BP in SLC8A1-transgenic mice 43 . Variants at SLC35F1 have previously been associated with resting heart rate and ventricular size, which could contribute to BP elevation 44 .
We also identify loci that are involved in cardiovascular development (GATA2, KIAA1462, FBN2, FN1 and HAND2) such as fibrillin 2 (FBN2), which overlaps in action with fibrillin 1 in development of the aortic matrix [45] [46] [47] [48] [49] . In addition, fibronectin expression is increased in hypertension and in atherosclerosis, but it may also have a role in the development of the heart [49] [50] [51] .
Our analysis validates loci containing genes with previous physiological connection to BP such as BDNF, FAM208A and CACNA2D2 (refs. 52-54) . The neurotrophin brain-derived neurotrophic factor (BDNF) modulates angiotensin 11 in the brain to elevate BP in experimental models; higher serum levels correlate with reduced risk of cardiovascular disease and mortality 52 . In experimental models, FAM208A, which is thought to be a transcription factor, is a strong candidate for a QTL of BP 54 . The gene CACNA2D2 encodes a subunit of the L-type calcium channel that is most abundantly expressed in the atrium and in neurons and may be a target for negatively chronotropic and inotropic calcium channel antagonists that reduce BP 55 .
We examine long-range genomic interactions using Hi-C, whereby we find promoter regions that have a strong chromatin interaction with a novel SNV. One example is EPAS1, which is ~200 kb away from the SNV (rs11690961). It encodes hypoxia-inducible factor 2α, which affects catecholamine homeostasis and protects against heart failure; mutations in the gene are associated with pulmonary hypertension 56 . Another such gene is INHBA, 1.3 Mb away from the SNV (rs12531683), the product of which is elevated in pulmonary hypertension and contributes to vascular remodeling by inducing expression of endothelin-1 and plasminogen activator inhibitor-1 in pulmonary smooth muscle cells 57 .
Our observation of BP that is 9-10 mm Hg higher at age 50 years and older when comparing the top and bottom fifths of the BP GRS distribution has potential clinical and public health implications. We stratified by age owing to a significant interaction of the GRS with age (P values ranging between 9.96 × 10 −11 and 1.16 × 10 −3 for interaction with continuous BP traits, P = 0.012 for hypertension). Measuring the GRS in early life increases the possibility of adopting an early precision medicine approach to offset genetic risk through lifestyle intervention (that is, reduced sodium intake, increased potassium intake, maintenance of optimal weight, low adult alcohol consumption and regular exercise) [58] [59] [60] . Studies of non-pharmacological approaches to BP control indicate that a reduction of 10 mm Hg or more in SBP is an achievable goal through lifestyle measures alone 61 , while recent evidence suggests that favorable lifestyle may offset the cardiovascular sequelae associated with high genetic risk 62 . As the above data are observational, the extent to which adherence to lifestyle recommendations among individuals at high genetic risk might result in favorable outcomes remains uncertain; given the substantial effect of the GRS on BP by middle age, the potential for adopting early lifestyle intervention among individuals at high genetic risk, along with populationwide measures to lower BP, warrants further study.
Since the completion of our study, another BP GWAS using UK Biobank data has been published 15 , as part of a larger single-stagecombined meta-analysis without replication; it reported a total of 316 loci, including 241 loci identified from the meta-analysis involving UK Biobank that were not tested for validation. Of the 107 validated loci reported in our study, 32 are discovered and validated for the first time in our analysis of UK Biobank. In addition, 75 sentinel SNVs are in LD (r 2 ≥ 0.2) with the recently reported loci 15 , and we validate at least 53 of these for the first time in our study (indicated by "GIU" in Tables 1-3) . Furthermore, we note that 49 of the reported loci from the recent study 15 did not validate in our large independent replication resource.
In summary we describe 107 validated loci for BP, offering new biology, identifying potential new therapeutic targets and raising the possibility of a precision medicine approach to modify risk of hypertension and cardiovascular outcomes. Altogether, this represents a major advance in understanding of the genetic architecture of BP. 
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ONLINE METhODS
UK Biobank data.
Our GWAS analysis is performed using data from the interim release of the first ~150,000 UK Biobank (UKB) participants (Supplementary Note): ~100,000 individuals from UK Biobank genotyped at ~800,000 SNVs with a custom Affymetrix UK Biobank Axiom array and ~50,000 individuals genotyped with a custom Affymetrix UK BiLEVE Axiom array from the UK BiLEVE study 63 , a subset of UKB. SNVs were imputed centrally by UKB using a merged UK10K sequencing + 1000 Genomes imputation reference panel. Information on UK Biobank array design and protocols is available on the UK Biobank website.
Quality control. Following quality control procedures already carried out centrally by UKB, we excluded discordant SNVs and samples with quality control failures, sex discordance and high heterozygosity/missingness. We further restricted our data to a subset of individuals of European ancestry. By applying k-means clustering to the principal-component analysis (PCA) data, a total of N = 145,315 Europeans remained (Supplementary Fig. 15 ). We used kinship data to exclude first-and second-degree relatives, with N = 141,647 unrelated individuals remaining. Finally, we restricted our data to non-pregnant individuals with two automated BP measurements available, resulting in a maximum of N = 140,886 individuals for analysis (Supplementary Note).
Phenotypic data. After calculating the mean SBP and DBP values from the two BP measurements, we adjusted for medication use by adding 15 and 10 mm Hg to SBP and DBP, respectively, for individuals reported to be taking BP-lowering medication (21.4% of individuals) 64 . PP was calculated as SBP minus DBP, according to the medication-adjusted traits. Hypertension, used in secondary analyses, was defined as (i) SBP ≥140 mm Hg, (ii) DBP ≥90 mm Hg, or (iii) taking BP-lowering medication; otherwise, individuals were classified as non-hypertensive. Descriptive summary statistics are provided for all individuals (Supplementary Table 1) .
Statistical methods. The statistical approaches used for the discovery and replication of loci are reported in detail below. We also describe methods used for identification of secondary signals; lookups in non-European populations and for monogenic BP genes; functional and experimental methods; and construction of a GRS for analysis with BP traits and cardiovascular outcomes. All P values are from two-sided tests.
Analysis models. For the GWAS, we performed linear regression analyses of the three (untransformed) continuous, medication-adjusted BP traits (SBP, DBP and PP) for all measured and imputed genetic variants in dosage format using SNPTEST software 65 under an additive genetic model. We carried out a similar analysis for the exome content. Quantile-quantile plots are shown in Supplementary Figure 16 . Each analysis included the following covariates: sex, age, age 2 , BMI, the top ten principal components and a binary indicator variable for UK Biobank versus UK BiLEVE to adjust for the different genotyping chips. We also ran an association analysis within UKB for validated BP-associated SNVs and hypertension using logistic regression under an additive model with adjustments as above. There were 76,554 hypertensive cases, and the 64,384 remaining participants were treated as non-hypertensive controls. This sample size is slightly larger than the N = 140,866 used in the main analyses, as participants with only one BP measurement but with reported BP-lowering medication could be included as hypertensive.
Previously reported variants.
We compiled a list of all SNVs previously reported to be associated with BP at the time of analysis (Supplementary Table 13 ). This list includes all published SNVs that have been identified and validated from previous GWAS, CardioMetabochip and exome chip projects [7] [8] [9] [10] [11] . We augmented this list to include all 34,459 SNVs in LD with these previously reported SNVs, according to a threshold of r 2 ≥ 0.2. Results for all these variants were extracted for each of the three BP traits, to check previously reported BP associations in the UKB data, according to whether the sentinel SNV or a variant at the locus in LD (r 2 ≥ 0.2) with it showed evidence of support (P < 0.01) for association with at least one of the three BP traits.
Replication strategy. We used three independent external data sets for replication (Supplementary Note). First, for the GWAS analysis based on advanced 1000 Genomes imputation enhanced by UK10K data, we considered SNVs with MAF ≥1% and performed a reciprocal replication exchange with the International Consortium of Blood Pressure (ICBP) 1000G meta-analysis (max N = 150,134). The imputation strategy for ICBP 1000G meta-analysis was based on an earlier imputation grid for the 1000 Genomes Project. In addition, we recruited further cohorts with 1000 Genomes data that had not contributed to the ICBP-1000G discovery meta-analysis: ASCOT-UK (N = 3,803), ASCOT-SC (N = 2,462), BRIGHT (N = 1,791), Generation Scotland (GS) (N = 9,749), EGCUT (N = 5,468), Lifelines (N = 13,292) and PREVEND (N = 3,619). This gave a total of N = 190,318 independent replication samples for the GWAS analysis.
Second, because the UK Biobank and UK BiLEVE genotyping chips contain exome content, we sought replication from two BP exome consortia (European exome consortium and the Cohorts for Heart and Aging Research in Genome Epidemiology (CHARGE) BP exome consortium), to allow validation of coding variants and variants with lower frequency. The European exome consortium (N = 161,926) and CHARGE consortium (N = 119,792) gave a total of N = 281,718 independent replication samples for the exome analysis.
Note that the lookups for GWAS and exome discovery were distinct sets of SNVs. Loci were assigned sequentially, prioritizing the primary GWAS discovery first and then considering any remaining loci with non-overlapping exome content for replication in the independent exome replication resources.
Statistical criteria for replication. For the GWAS discovery, there were ~9.8 million SNVs with MAF ≥1% and INFO >0.1. We considered for followup any SNVs with P < 1 × 10 −6 for any of the three BP traits. For the exome discovery, there were 149,026 exome SNVs (Supplementary Note) that were polymorphic with INFO >0.1; for follow-up, we considered all SNVs with MAF ≥0.01% and P < 1 × 10 −5 . All such SNVs were annotated to loci according to both an LD threshold of r 2 ≥ 0.2 and a 1-Mb interval (Supplementary Note), and signals were classified either as belonging to unvalidated loci or being potential secondary signals at previously reported loci at the time of analysis.
Selection of variants for follow-up. The sentinel (most significant) SNV from each association signal was selected for follow-up, all of which were pairwise independent by LD (r 2 < 0.2). For the GWAS discovery, we checked that potential lookup SNVs were covered in the ICBP-1000G replication data (Supplementary Tables 28 and 29 , and Supplementary Note). Of the 235 novel loci containing previously unreported SNVs at the time of analysis with MAF ≥1%, INFO >0.1 and P < 1 × 10 −6 , 218 were covered, and similarly 100 of the 123 potential secondary SNVs at 51 of the 54 previously reported BP loci at the time of analysis were available for follow-up. For the exome discovery, by following up SNVs with MAF ≥0.01%, INFO >0.1 and P < 1 × 10 −5 across the three BP traits, we carried forward for replication sentinel SNVs at 22 unvalidated loci and potential secondary SNVs at 3 previously reported loci at the time of analysis. We produced LocusZoom plots for each of the lookup variants.
Replication meta-analyses. The replication and combined meta-analyses were performed within METAL software 66 using fixed-effects inverse-varianceweighted meta-analysis (Supplementary Note). The combined meta-analysis of both the UKB discovery (N = 140,886) and GWAS replication meta-analysis (max N = 190,070) included a total maximum sample size of N = 330,956. For the exome combined meta-analysis, we synthesized data from the UKB discovery exome content (max N = 140,866) with the replication data set from both exome consortia (total max N = 281,718), giving a maximum sample size of N = 422,604.
Validation criteria. In our study, a signal was declared to be validated if it satisfied all three of the following criteria: (i) the sentinel SNV was genomewide significant (P < 5 × 10 −8 ) in the combined meta-analysis for any of the three BP traits; (ii) the sentinel SNV showed evidence of support (P < 0.01) in the replication meta-analysis alone for association with the most significantly associated BP trait from the combined meta-analysis (N.B.: P < 0.01 is more stringent than a range of thresholds calculated according to FDR; Supplementary Note); and (iii) the sentinel SNV had concordant directions of effect between the UKB discovery and the replication meta-analysis for the most significantly associated BP trait from the combined meta-analysis.
Secondary signals.
By conditional analysis within UKB data, we assessed all validated secondary signals from our validated and previously reported loci at the time of analysis for independence from the sentinel or previously reported SNV, respectively (Supplementary Note). We declared a secondary signal to be independent of the previously reported SNV if there was less than a 1.5-fold difference between the main association and conditional association P values on a −log 10 scale, i.e., if −log 10 (P)/−log 10 (P cond ) < 1.5. Note that the lookup criteria already ensured that the secondary variant was not in LD (r 2 < 0.2) with the previously reported SNV. If more than one SNV in a region was found to be independent, we undertook further rounds of iterative conditional analysis.
Lookups in non-European ancestries. As a secondary analysis, we looked up 102 and 5 validated SNVs from the GWAS and exome analyses, respectively, in non-European ancestry samples. These comprised analysis of East Asian (N = 31,513) and South Asian (N = 33,115) ancestry data from the iGEN-BP consortium 11 for the GWAS lookups and South Asian (N = 25,937), African-American (N = 21,488) and Hispanic (N = 4,581) ancestry data from the CHARGE BP exome consortium 10 and CHD+ Exome consortium 9 for the exome content lookups (Supplementary Note). We carried out a binomial (sign) test based on the number of SNVs with consistent directions of effect between UKB and each of the samples of non-European ancestry.
Monogenic blood pressure gene lookups. The UKB arrays include some rare coding variants for monogenic disorders. We collated a list of all specific mutations within genes known to be associated with monogenic BP disorders 19 . Results from the UKB association analyses for all three BP traits were extracted for any of these SNVs directly covered in the UKB data set (Supplementary Table 14 ). Note that a search of proxies did not augment the list of available variants, so results are reported for the specific variants only.
Functional analyses.
To prioritize associated SNVs, we used an integrative bioinformatics approach to collate functional annotation (Supplementary Table 30 ) at both the variant and gene level for each SNV within the BP loci (all SNVs in LD r 2 ≥ 0.8 with the BP-associated SNVs). At the variant level, we used ANNOVAR 67 to obtain comprehensive functional characterization of variants, including gene location, conservation and amino acid substitution impact based on a range of prediction tools including SIFT and PolyPhen-2. All nonsynonymous variants were predicted to be damaging by two or more methods.
We used the UCSC Genome Browser to review the sequence-specific context of SNVs in relation to function, particularly in the Encyclopedia of DNA Elements (ENCODE) data set 68 . We used the UCSC table browser to annotate SNVs in ENCODE regulatory regions. We evaluated SNVs for impact on putative miRNA target sites in the 3′ UTRs of transcripts by a query of the miRNASNP database 69 . We evaluated all SNVs in LD (r 2 ≥ 0.8) with our validated sentinel SNVs for evidence of mediation of eQTLs in all 44 tissues using the GTEx database, to identify validated loci that are highly expressed and to highlight specific tissue types that show eQTLs for a large proportion of validated loci. We further sought to identify validated loci with the strongest evidence of eQTL associations in arterial tissue in particular.
At the gene level, we used Ingenuity Pathway Analysis (IPA) software (IPA, Qiagen) to review genes with prior links to BP, on the basis of annotation with the "Blood Pressure" Medline Subject Heading (MESH) term, which is annotated to 684 genes. We also used IPA to identify genes that interact with BP MESH-annotated genes and evaluated genes for evidence of small molecule druggability on the basis of queries of the Chembl and Drug Gene Interaction database.
We then performed overall enrichment testing across all loci. First, we used DEPICT 70 (Data-driven Expression-Prioritized Integration for Complex Traits) to identify tissues and cells in which the BP loci were highly expressed. DEPICT uses a large number of microarrays (~37,000) to identify cells and tissues where the genes are highly expressed and uses precomputed GWAS phenotypes to adjust for co-founding sources. DEPICT provides a P value of enrichment and an FDR-adjusted P value for each tissue and cell type tested.
Furthermore, to investigate regulatory regions, we employed a two-tiered approach to investigate cell-type-specific enrichment within DNase Ihypersensitive sites using FORGE, which tests for enrichment of SNVs within DNase I-hypersensitive sites in 123 cell types from the Epigenomics Roadmap Project and ENCODE 71 (Supplementary Note). Validated sentinel SNVs from our study were analyzed along with previously reported SNVs at the time of analysis and secondary signals (with P < 1 × 10 −4 ) to evaluate the overall tissue-specific enrichment of BP-associated variants. In a second analysis, we used FORGE (with no LD filter) to investigate directly our curated candidate regulatory SNVs for overlap with cell-type-specific DNase I-hypersensitive signals.
GenomeRunner 72 was used to search for enrichment of validated and previously reported sentinel SNVs with histone modification mark genomic features (Supplementary Note). Relevant cardiovascular tissue expression was investigated using Fantom5 reference transcript expression data (http://fantom.gsc.riken.jp/5) (Supplementary Note).
We used IPA to identify biological pathways and transcriptional upstream regulators enriched for genes within the BP loci. The transcriptional upstream regulator analysis aimed to identify transcription factors, compounds, drugs, kinases and other molecules for which the target is one of the BP-associated genes under investigation.
We queried SNVs against PhenoScanner 16 to investigate trait pleiotropy, extracting all association results with nominal significance at P < 0.05 for full reporting (Supplementary Table 16) , and then extracted genome-wide significant results to highlight the validated loci with the strongest evidence of association with other traits (Supplementary Fig. 5a ). We also used the Genomic Regions Enrichment of Annotations Tool (GREAT) to study gene set enrichment of mouse phenotype and disease ontology terms within our validated and previously reported loci at the time of analysis, using default SNV-to-gene mapping settings 73 .
We carried out metabolomics analysis using two sets of data. First, we used 1 H NMR lipidomics data on plasma from a subset of 2,000 participants of the Airwave Health Monitoring Study 74, 75 (Supplementary Note). For each validated BP-associated SNV, we ran association tests with the lipidomics data using linear regression analyses, adjusted for age and sex. We computed significance thresholds using a permutation-derived family-wise error rate (5%) to account for the high correlation structure of these data (ENT = 35) (ref. 76 ). We also tested each validated SNV against published genome-wide versus metabolome-wide associations in plasma and urine using publicly available data from the Metabolomics GWAS Server to identify metabolites that have been associated with variants of interest at P < 3.0 × 10 −4 (Bonferronicorrected P value for validated signals) 22, 23 .
Experimental methods. We prioritized genes for laboratory testing on the basis of evidence of SNV function (including coding variants, eQTLs and Hi-C interactions), biological support for relevance to BP (from literature review) and mouse transgenic phenotype. We performed genotyping and qRT-PCR for the selected sentinel variants of interest using human VSMCs and endothelial cells and tested for expression levels (Supplementary Table 31 and Supplementary Note). All three SNVs were tested using an additive model.
Genetic risk scores.
GRSs were constructed using data from the independent Airwave study 74 to assess the combined effect of the BP-associated variants on BP and risk of hypertension (Supplementary Note), while avoiding bias from 'winner's curse' . We created weighted GRSs for all pairwise-independent, LDfiltered (r 2 < 0.2) previously reported variants at the time of analysis and our validated variants (sentinel and secondary SNVs) combined, using available SNVs (Supplementary Table 22) . For the previously reported variants at the time of analysis, we weighted BP-increasing alleles by the β coefficients from the UKB analysis. For our validated variants, the β coefficients of the replication meta-analysis were used as independent, unbiased weights.
For analyses of the variance explained within the independent Airwave cohort, we used three trait-specific GRSs (SBP, DBP and PP). Each GRS included all variants, but weights were trait specific, using the β coefficients from the analysis of each of the three different BP traits; for example, the SBP GRS was weighted by the β coefficients from the SBP GWAS. To calculate the percent of variance for each BP trait explained by its corresponding trait-specific GRS, not accounted for by known factors, we generated the residuals from the regression model of each trait against covariates of age, age 2 , sex and BMI. We then fit a second linear model for the trait residuals with all the variants in the GRS plus the top ten principal components.
For risk score analyses, we calculated a single BP GRS, as the average of the SBP and DBP GRSs. We standardized the average GRS to have mean of 0 and s.d. of 1. We assessed the association of the continuous average GRS variable with each BP trait by simple linear regression. We also ran logistic regression to examine the association of the average GRS with risk of hypertension. We performed each analysis both with and without adjustment for sex. We tested for interaction between age (<50 years and ≥50 years) and the effect of the GRS on BP. We then compared BP levels and risk of hypertension for individuals in the top and bottom 20% of the GRS distribution at ≥50 years of age using linear and logistic regression, respectively.
We also assessed the association of the average BP GRS with cardiovascular outcomes in the UKB data. We included all pairwise-independent previously reported BP variants at the time of analysis and our validated variants. We used logistic regression with binary outcome variables for coronary heart disease, stroke and cardiovascular disease (Supplementary Note) and the GRS as an explanatory variable (with and without sex adjustment).
Data availability. The data generated during the current study are available from the UK Biobank data repository (http://biota.osc.ox.ac.uk/), which can be accessed by researchers upon application. These data include the derived GWAS analysis summary data from our UK Biobank discovery data for all three BP traits. The genetic and phenotypic UK Biobank data are also available upon application to the UK Biobank (https://www.ukbiobank.ac.uk/). All replication data generated during this study are included in the published article. For example, association results of lookup variants from our replication analyses and the subsequent combined meta-analyses are contained within the supplementary tables provided.
